Welcome to LookChem.com Sign In|Join Free

CAS

  • or

88105-29-7

Post Buying Request

88105-29-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • b-D-Glucopyranoside, (3b,12b)-3-(b-D-glucopyranosyloxy)-12-hydroxydammar-24-en-20-yl 6-O-a-L-arabinofuranosyl- 88105-29-7

    Cas No: 88105-29-7

  • No Data

  • 1 Kilogram

  • 10000 Metric Ton/Month

  • Shanghai Upbio Tech Co.,Ltd
  • Contact Supplier

88105-29-7 Usage

Description

Notoginseng triterpenes (NTs) are the bioactive components derived from the traditional Chinese medicinal herb, Panax notoginseng. They are known for their ability to reduce oxygen consumption and enhance the body's tolerance to hypoxia. NTs have been studied for their potential role in improving the survival of random skin flaps by promoting cell proliferation, migration, and increasing blood perfusion.
Used in Pharmaceutical Industry:
Notoginseng triterpenes are used as immunomodulatory and anti-inflammatory agents for their therapeutic effects on various conditions. Notoginsenoside Fe, a specific compound within NTs, is particularly known for its medicinal properties.
Used in Skin Regeneration and Wound Healing:
Notoginseng triterpenes are used as a treatment to improve the survival area of skin flaps in random skin flap models. They promote cell proliferation and migration, as well as increase blood perfusion, which contributes to the healing process and overall success of skin flap surgeries.

Biological Activity

Notoginsenoside Fe is a saponin and metabolite of ginsenoside Rc (Item No. 29088) that has been found in P. notoginseng. It is cytotoxic to L1210 murine skin lymphocytic leukemia cells (IC50 = 80 μM).

Check Digit Verification of cas no

The CAS Registry Mumber 88105-29-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,8,1,0 and 5 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 88105-29:
(7*8)+(6*8)+(5*1)+(4*0)+(3*5)+(2*2)+(1*9)=137
137 % 10 = 7
So 88105-29-7 is a valid CAS Registry Number.

88105-29-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name β-D-Glucopyranoside, (3β,12β)-3-(β-D-glucopyranosyloxy)-12-hydroxydammar-24-en-20-yl 6-O-α-L-arabinofuranosyl-

1.2 Other means of identification

Product number -
Other names Sanqi tofal Saponins

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:88105-29-7 SDS

88105-29-7Upstream product

88105-29-7Downstream Products

88105-29-7Relevant articles and documents

Ginsenoside Mc1 improves liver steatosis and insulin resistance by attenuating ER stress

Baik, Sei Hyun,Choi, Kyung Mook,Hong, So-hyeon,Hwang, Hwan-Jin,Kim, Joo Won,Kim, Jung A,Lee, You-Bin,Roh, Eun,Yoo, Hye Jin

, (2020)

Ethnopharmacological relevance: Ginsenoside, a major pharmacologically active ingredient in ginseng, has been known to exhibit beneficial properties such as antioxidant and anti-inflammatory effects. Ginsenoside compound Mc1 is one of the newly identified de-glycosylated ginsenosides. Endoplasmic reticulum (ER) stress has implicated in the development of non-alcoholic fatty liver disease (NAFLD) through apoptosis and lipid accumulation. Aim of the study: We aimed to examine the protective effects of Mc1 treatment on ER stress-induced cell death and impaired insulin signaling in HepG2 human hepatoblastoma cells and ER stress-induced liver steatosis and insulin resistance in a diet-induced obesity (DIO) mouse model. Materials and methods: HepG2 cells were treated with palmitate and Mc1 to evaluate the effects of Mc1 on ER stress-induced damage. C57BL/6 mice were fed with a high-fat diet (HFD) for 4 weeks and received an intraperitoneal injection of either vehicle or Mc1 (10 mg/kg/day). The control mice were fed with a chow diet and injected with vehicle for the same period. ER stress, cell death, and degree of steatosis were evaluated in the liver tissues of mice. The effect of Mc1 treatment on glucose metabolism was also determined. Results: Mc1 co-treatment reduced the palmitate-induced ER stress and death of HepG2 cells. The palmitate-induced insulin resistance improved after Mc1 co-treatment. Consistent with the in vitro data, chronic Mc1 supplementation reduced ER stress and apoptotic damage in the liver of obese mice. Mc1 treatment ameliorated glucose intolerance and insulin resistance through the suppression of c-Jun N-terminal kinase (JNK) phosphorylation. In addition, Mc1 treatment reduced obesity-induced lipogenesis and prevented fat accumulation in the liver of DIO mice. Conclusions: Mc1 exerted protective effects against ER stress-induced apoptotic damage, insulin resistance and lipogenesis in palmitate-treated hepatocytes and in the liver of DIO mice. Therefore, Mc1 supplementation could be a potential therapeutic strategy to prevent NAFLD in patients with obesity and insulin resistance.

Rational design of a β-glycosidase with high regiospecificity for triterpenoid tailoring

Park, Sang Jin,Choi, Jung Min,Kyeong, Hyun-Ho,Kim, Song-Gun,Kim, Hak-Sung

, p. 854 - 860 (2015/03/30)

Triterpenoids with desired glycosylation patterns have attracted considerable attention as potential therapeutics for inflammatory diseases and various types of cancer. Sugar-hydrolyzing enzymes with high substrate specificity would be far more efficient than other methods for the synthesis of such specialty triterpenoids, but they are yet to be developed. Here we present a strategy to rationally design a β-glycosidase with high regiospecificity for triterpenoids. A β-glycosidase with broad substrate specificity was isolated, and its crystal structure was determined at 2.0 ? resolution. Based on the product profiles and substrate docking simulations, we modeled the substrate binding modes of the enzyme. From the model, the substrate binding cleft of the enzyme was redesigned in a manner that preferentially hydrolyzes glycans at specific glycosylation sites of triterpenoids. The designed mutants were shown to produce a variety of specialty triterpenoids with high purity.

Biotransformation of ginsenoside Rc into C-Mc1 by the bacterium sphingopyxis sp. BG97

Ten,Chae,Yoo

, p. 565 - 567 (2014/08/18)

-

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 88105-29-7